Description
Release form
Capsules 500 mg. 10 capsules per blister of PVC / AL. 3 blisters with instructions for use in a cardboard pack.
Pharmacological action
Pharmacodynamics
Angioprotector, reduces increased vascular permeability, increases capillary wall resistance, improves microcirculation and drainage function of lymphatic vessels, moderately reduces platelet aggregation and blood viscosity, increases erythrocyte membrane elasticity. The action is associated to a certain extent with an increase in the activity of plasma kinins.
Pharmacokinetics
Rapidly absorbed in the gastrointestinal tract. The maximum concentration in blood plasma is reached 6 hours after ingestion. Binding to plasma proteins is 20-25%. Almost does not penetrate the blood-brain barrier.
It is excreted by the kidneys (about 50%) and through the intestines (about 50%) mainly in unchanged form for 24 hours, 10% – in the form of metabolites. The half-life is 5 hours.
In very small quantities (0.4 μg / ml after taking 1.5 g of the drug), excreted in breast milk.
Indications
Vascular lesions with increased fragility and permeability of capillaries (diabetic retinopathy and nephropathy) and other microangiopathies associated with various cardiovascular and metabolic diseases.
Venous insufficiency of varying severity and its consequences (pre-varicose veins with swelling of the tissues, pain, paresthesias, congestive dermatosis, superficial phlebitis, varicose veins, trophic ulcers).
Contraindications
Hypersensitivity to calcium dobesilate or any component of the drug, peptic ulcer of the stomach and 12 duodenal ulcer (in the acute stage), bleeding from the gastrointestinal tract, kidney and liver diseases, hemorrhages caused by anticoagulants pregnancy (I trimester), children ( up to 13 years old).
Use during pregnancy and lactation
Adequate and strictly controlled studies of the safety of use in pregnant and lactating women have not been conducted. The use of the drug is contraindicated in the first trimester of pregnancy. In the second and third trimesters of pregnancy, the drug is prescribed only for health reasons if the expected effect of the application exceeds the possible risk to the fetus.
With the appointment during lactation, it is necessary to decide on the termination of breastfeeding.
Special instructions
The drug can be prescribed prophylactically.
When symptoms of agranulocytosis appear (fever, headache, chills, weakness, pain when swallowing, inflammation of the oral mucosa), you should immediately consult a doctor and conduct a clinical blood test.
Calcium dobesilate may interfere with laboratory test results to determine creatinine levels.
Effect on the ability to drive vehicles and work with mechanisms
The drug does not adversely affect the ability to drive vehicles and work with mechanisms.
Composition
1 capsule contains the active substance: (in the form of calcium dobesylate monohydrate 521.51 mg) – 500.00 mg
excipients: corn starch – 25.164 mg, magnesium stearate – 8.326 mg
Capsule No. 0: case: titanium dioxide E171 – 0.8640 mg, iron dye oxide yellow E172-0.1440 mg
cap: dye eza oxide E 172 black – 0.1920 mg indigo carmine dye E132 – 0.1728 mg Titanium dioxide E171 – 0.4800 mg ferric oxide yellow colorant E172 – 0.5760 mg to 96 mg of gelatin.
Dosage and administration
Inside, without chewing, with food.
Assign 500 mg 3 times a day for 2-3 weeks, then reduce the dose to 500 mg once a day. In the treatment of retinopathy and microangiopathy, 500 mg is prescribed 3 times a day for 4-6 months, then the daily dose is reduced to 500 mg 1 time per day.
The course of treatment is from 3-4 weeks to several months, depending on the therapeutic effect.
Side effects
Classification of adverse reactions according to the frequency of development: often – 1-10%, infrequently – 0.1-1%, rarely – 0.01-0.1%, very rarely, including some cases – <0.01 % Disorders of the gastrointestinal tract. Rarely: nausea, diarrhea, vomiting. Disorders of the skin and subcutaneous tissue. Rarely: allergic reactions (itching, rash). General Disorders. Rarely: fever, chills. Disorders of the musculoskeletal and connective tissue. Rarely: arthralgia. Disorders of the blood and lymphatic system. In some cases: agranulocytosis. The reaction is reversible and disappears after discontinuation of therapy. Drug Interactions Cases of drug interactions of calcium dobesilate have not yet been identified. Overdose There have been no cases of overdose. Storage conditions At a temperature not exceeding 25 ° C in consumer packaging. Keep out of the reach and sight of children. Term hodnosty 5 years Active ingredient Calcium dobesilate Terms leave through pharmacies In retseptu lekarstvennaja form kapsul Prescription Adults prescribed by a doctor, Children over 13 years old, Pregnant women II and III trimester as prescribed by a doctor, Children prescribed by a doctor Indications Indications From diabetic retinopathy, From trophic ulcers, In case of diabetic nephropathy
